Information Provided By: 
Fly News Breaks for November 6, 2019
BCRX
Nov 6, 2019 | 11:21 EDT
Piper Jaffray analyst Tyler Van Buren said following the presentation of new data showing that BCX7353 continues to show sustained efficacy through 48 weeks, he believes BCX7353 is an "approvable, viable" product that is also demonstrating durability. BioCryst also has several other products in the pipeline - such as BCX9930 and BCX9350 - are receiving no value from investors, added Van Buren, who keeps an Overweight rating and $10 price target on the shares.
News For BCRX From the Last 2 Days
There are no results for your query BCRX
